Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in pretargeting biotechnology.

D A Goodwin1, C F Meares

  • 1Nuclear Medicine Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA. goodwinda83@hotmail.com

Biotechnology Advances
|October 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancement of skin penetration of nonsteroidal anti-inflammatory drugs from extemporaneously compounded topical-gel formulations.

International journal of pharmaceutical compounding·2013
Same author

The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex.

Journal of the American Chemical Society·2011
Same author

Diffusion-enhanced lanthanide energy transfer studies of protein prosthetic groups.

Biophysical journal·2009
Same author

Pathological implications of iNOS expression in central white matter: an ex vivo study of optic nerves from rats with experimental allergic encephalomyelitis.

The European journal of neuroscience·2005
Same author

Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve.

Neuroscience·2002
Same author

Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.

Molecular pharmacology·2001
Same journal

Biosensors with enzymatic amplification strategies for the detection of foodborne pathogenic microorganisms.

Biotechnology advances·2026
Same journal

Cell surface display for nutritional chemicals: Strategies, mechanisms, and evaluation methods.

Biotechnology advances·2026
Same journal

Advancing synthetic biology with engineered chemically inducible gene regulatory systems.

Biotechnology advances·2026
Same journal

Technology-driven revolution in CO<sub>2</sub> fixation: From natural pathways to programmable Biosystems.

Biotechnology advances·2026
Same journal

Enzymes for CO<sub>2</sub> fixation: Discovery, engineering, and applications.

Biotechnology advances·2026
Same journal

Technological advances in extrachromosomal circular DNA detection.

Biotechnology advances·2026
See all related articles

Improving drug targeting for cancer therapy is crucial. Recent advances in pretargeting biotechnology offer new ways to concentrate drugs at tumor sites, minimizing side effects for better treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Drug targeting aims to enhance therapeutic efficacy by concentrating agents at specific internal sites like solid tumors.
  • Current methods using radiolabeled antibodies for tumor targeting face challenges with normal organ uptake, including blood, kidneys, liver, and bone marrow.
  • Strategies to improve antibody-based therapies over the past two decades include antibody fragments, ADEPT, and pretargeting.

Purpose of the Study:

  • To review recent advancements in pretargeting biotechnology for improved drug delivery.
  • To highlight innovations aimed at enhancing drug concentration at target sites, particularly for cancer therapy and radioimmunotherapy.
  • To discuss methods for minimizing off-target effects of therapeutic agents.

Main Methods:

Related Experiment Videos

  • Review of recent scientific literature and technological developments in pretargeting biotechnology.
  • Analysis of strategies employed to improve antibody-based drug targeting, including antibody fragments, chase molecules, and ADEPT.
  • Focus on pretargeting as a key approach to enhance therapeutic agent localization.

Main Results:

  • Pretargeting biotechnology has emerged as a significant area of research for improving drug targeting.
  • Various techniques have been developed to enhance drug concentration at target sites and reduce systemic toxicity.
  • Advances in pretargeting offer promising solutions for more effective cancer chemotherapy and radioimmunotherapy.

Conclusions:

  • Pretargeting biotechnology represents a key area of innovation for enhancing the specificity and efficacy of internal drug targeting.
  • Continued research in pretargeting strategies is essential for overcoming limitations in current cancer therapies and radioimmunotherapy.
  • Optimizing pretargeting approaches can lead to improved therapeutic outcomes with reduced side effects.